Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by M&T Bank Corp
M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...
The Pharma Letter15d
Phase IV Ingrezza data move focus from sales outlook
Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that Ingrezza (valbenazine) provided meaningful and sustained benefits for patients ...
Too Old to Operate17d
Ad Code: Ingrezza - High Opp Display Banners Knowledge Hub - Feb - 216928
It is important for clinicians to understand the causes and symptoms of tardive dyskinesia to avoid common misdiagnoses and ensure effective management.
Neurocrine price target lowered to $183 from $191 at JPMorgan
JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated ...
Nasdaq22d
Neurocrine Board Authorizes Share Repurchase Program - Quick Facts
INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders." For More Such Health News, visit rttnews.com. The views and opinions expressed herein are the ...
The Victoria Advocate22d
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
INGREZZA and CRENESSITY, advancing our expanding R&D pipeline and returning capital to shareholders." Under the new authorization, repurchases may be made from time to time at management's ...
Hosted on MSN28d
Neurocrine Biosciences CFO sells shares worth $298,922
This revision follows the company's announcement that Ingrezza, its flagship product ... For more information see our T&C.